BIOCRATES and ALTANA Pharma Expand Metabolomics Collaboration
April 06 2006 - 11:00AM
PR Newswire (US)
INNSBRUCK, Austria, April 6 /PRNewswire/ -- Based on successful
pilot studies in high-resolution pharmacodynamics, BIOCRATES Life
Sciences GmbH and ALTANA Pharma AG signed a collaboration contract
comprising joint method development for targeted metabolite
profiling as well as further preclinical and clinical studies. "We
are very pleased to gain an innovative pharma partner like ALTANA
Pharma in one of our main business areas," said Armin Graber Ph.D.,
BIOCRATES' CEO. "This collaboration will broaden our analytical
panel and adapt it to the needs of the pharmaceutical industry."
The medical focus of the joint projects will be on a better
understanding of inflammatory processes in respiratory diseases in
view of the development of novel multiparametric biomarkers for
drug development and therapy monitoring. "A targeted and
quantitative approach to metabolomics allows to immediately deduce
biologically relevant information from the analytical data," says
Klaus Weinberger Ph.D., CSO of BIOCRATES. "Important enzymatic
reactions and entire metabolic pathways can now be monitored on a
fully standardized basis." "Pilot studies in disease model
characterization and pharmacodynamics have impressively
demonstrated the huge potential of this technology for drug
development," adds Sascha Dammeier Ph.D., Head of Protein
Technologies at ALTANA Pharma AG. "We aim at exploiting this
potential to obtain additional relevant mode-of-action data in many
steps of preclinical and clinical drug development." About
BIOCRATES Life Sciences GmbH BIOCRATES life sciences, a provider of
high content metabolome information and technology, develops
application systems and consumable-based products for
pharmaceutical research and development and clinical diagnostics.
The targeted metabolomics platform comprises fully automated sample
preparation procedures and software linked to mass
spectrometry-based analytics. The quantitative metabolite profiling
approach enables routine high-content screening and standardized
wide-spread use of metabolomics technology. In partnership with
pharmaceutical, biotechnology and nutrition companies, BIOCRATES
life sciences uses its technology to speed drug discovery
processes, reduce late-stage drug attrition due to adverse
reactions, discover new biomarkers and develop early tests for
monitoring drug response. BIOCRATES life sciences' technology is
also applied to validate and prioritize drug targets, identify
novel applications for existing drugs and improve drug safety by
analyzing the pharmacological and toxicological effects of a
substance with unprecedented resolution and sensitivity.
Information about BIOCRATES life sciences is available at
http://www.biocrates.at/. About ALTANA Pharma ALTANA Pharma AG is
the pharmaceutical division of ALTANA AG (FSE: ALT), (NYSE:AAA),
headquartered in Konstanz, Germany. ALTANA Pharma is an
internationally successful, research-based company providing
innovative pharmaceuticals that create a higher quality of life for
patients, modern jobs for highly qualified employees and a good
return for shareholders. The product range of ALTANA Pharma focuses
on therapeutics for the treatment of gastrointestinal and
respiratory diseases, which the company develops with intense
research commitment. Further information is available on the
Internet at http://www.altanapharma.com/. This release was issued
through WebWire(R). For more information visit
http://www.webwire.com/. DATASOURCE: BIOCRATES Life Sciences
CONTACT: Dr. Klaus Weinberger, CSO of BIOCRATES Life Sciences, +43
512 579823, or Web site: http://www.biocrates.at/
http://www.altanapharma.com/
Copyright
Altana (NYSE:AAA)
Historical Stock Chart
From Apr 2024 to May 2024
Altana (NYSE:AAA)
Historical Stock Chart
From May 2023 to May 2024